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ARTICLE
ATR inhibition facilitates targeting of leukemia
dependence on convergent nucleotide biosynthetic
pathways
Thuc M. Le1,2, Soumya Poddar1,2, Joseph R. Capri1,2, Evan R. Abt1,2, Woosuk Kim1,2, Liu Wei1,2, Nhu T. Uong1,2,
Chloe M. Cheng1,2, Daniel Braas1,3,4, Mina Nikanjam5, Peter Rix6, Daria Merkurjev7, Jesse Zaretsky1,4,
Harley I. Kornblum1,8,9,10, Antoni Ribas1,4,5,9,11,12, Harvey R. Herschman1,2,4,13, Julian Whitelegge14,
Kym F. Faull1,2,14, Timothy R. Donahue1,2,4,11, Johannes Czernin1,2 & Caius G. Radu 1,2
Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to
produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phospho-
proteomic approaches, we show that inhibition of the replication stress sensing kinase ataxia
telangiectasia and Rad3-related protein (ATR) reduces the output of both de novo
and salvage pathways by regulating the activity of their respective rate-limiting enzymes,
ribonucleotide reductase (RNR) and deoxycytidine kinase (dCK), via distinct molecular
mechanisms. Quantification of nucleotide biosynthesis in ATR-inhibited acute lymphoblastic
leukemia (ALL) cells reveals substantial remaining de novo and salvage activities, and could
not eliminate the disease in vivo. However, targeting these remaining activities with RNR and
dCK inhibitors triggers lethal replication stress in vitro and long-term disease-free survival
in mice with B-ALL, without detectable toxicity. Thus the functional interplay between
alternative nucleotide biosynthetic routes and ATR provides therapeutic opportunities in
leukemia and potentially other cancers.
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Unabated proliferation is a hallmark of cancer whichrequires new DNA synthesis from deoxyribonucleotidetriphosphates (dNTPs). However, cellular dNTP levels
only suffice to sustain a few minutes of DNA replication indi-
cating that dNTP pools are produced ‘on demand’ via tightly
regulated biosynthetic pathways1. These deoxynucleotide bio-
synthetic pathways, termed de novo and salvage, rely on distinct
carbon and nitrogen sources2. De novo pathways use glucose and
amino acids to produce ribonucleotide diphosphates (rNDPs)
which are converted into deoxyribonucleotide diphosphates
(dNDPs) by ribonucleotide reductase (RNR), a two-subunit
enzyme complex3 upregulated in most cancers4. Salvage pathways
convert preformed ribonucleosides, deoxyribonucleosides and
nucleobases into nucleotides through the actions of metabolic
kinases and phosphoribosyltransferases2. Amongst nucleoside
salvage kinases, deoxycytidine kinase (dCK) has the broadest
substrate specificity, encompassing both purine and pyrimidine
nucleosides5. While tumors are thought to predominantly rely on
de novo pathways to produce nucleotides6, scavenging of
preformed nucleosides via dCK and other salvage kinases may
also play important roles in the economy of nucleotide metabo-
lism in cancer cells. Many of the cell lines included in the Cancer
Cell Line Encyclopedia7, 8 express dCK at higher levels than the
corresponding normal tissues. Increased tumor dCK expression
relative to matched normal tissues also occurs in patient samples,
as evidenced by RNASeq data from The Cancer Genome Atlas
(TCGA, http://cancergenome.nih.gov)9, 10. Moreover, in vivo,
cancer cells often encounter limited supplies of essential de novo
pathway substrates, e.g., glucose, glutamine and aspartate, because
of their avid consumption of these nutrients and inadequate
vascularization11. An insufficient de novo biosynthetic capacity,
coupled with an increased demand for dNTPs due to unabated
proliferation, might increase the dependency of certain tumors on
salvage pathways for nucleotide production. Consistently, we
previously showed that acute lymphoblastic leukemia (ALL) cells
display nucleotide biosynthetic plasticity12, defined as the ability
to compensate for the inhibition of either de novo or salvage
pathways by upregulating the alternate pathway. These metabolic
transitions occurred both in vitro and in vivo; moreover,
partial inhibition of both de novo and salvage biosynthetic
routes was required for therapeutic activity in animal models of
T and B-ALL12.
Collectively, these results suggest that, in acute leukemia, and
potentially in other cancers, nucleoside salvage biosynthetic
pathways may be metabolic non-oncogene addictions13 targetable
by specific inhibitors. However, since both de novo and salvage
biosynthetic pathways also operate in normal cells14, 15, a better
understanding of the signaling mechanisms that regulate their
activity in cancer cells may lead to the development of more
effective targeted therapies. In this context, the mTOR16–18,
Myc19, 20 and Ras21 pathways have been shown to regulate
nucleotide biosynthesis. The replication stress response pathway
also plays important roles in regulating nucleotide metabolism,
given its unique ability to ‘sense’ dNTP insufficiency22. The most
proximal enzyme in the cellular response to replication stress is
ataxia telangiectasia and Rad3-related protein (ATR), a serine
threonine kinase activated at stalled replication forks23 in
response to nucleotide insufficiency and other replication defects.
In addition to its well-established role in regulating origin firing
and promoting fork stability24, ATR has been recently linked to
nucleotide metabolism. Inhibition of ATR, or of its downstream
effector kinases CHEK1 and WEE1, reduces dNTP levels in
cancer cell lines25. This effect of ATR inhibition was proposed to
involve the downregulation of the small RNR subunit RRM2,
particularly at the G1/S transition26, 27. Intriguingly, ATR also
regulates dCK activity in several solid tumor and myeloid
leukemia cells by phosphorylation at serine 7428). This post-
translational modification (PTM) modulates dCK’s catalytic
properties and substrate specificity29, 30. While collectively these
findings support a connection between ATR signaling and dNTP
production, the metabolic consequences of ATR inhibition in
malignancies with nucleotide biosynthetic plasticity are yet to be
defined.
Here, we examine ATR modulation of dNTP synthesis and
utilization for DNA synthesis, and the consequences for tumor
cell viability in culture and in vivo in ALL models, using quan-
titative approaches. Our targeted multiplexed mass spectrometric
(MS) assay measures the differential contributions of the de novo
and salvage pathways both to nucleotide pools and newly repli-
cated DNA. This assay is used in conjunction with proteomic and
phosphoproteomic MS approaches to investigate the mechanisms
responsible for alterations in nucleotide biosynthesis induced by
ATR inhibition. In addition, we compare direct targeting of de
novo and salvage rate-limiting enzymes, using specific inhibitors
vs. indirect inhibition of these enzymes via interference with ATR
signaling. These studies identify a synthetically lethal interaction
between inhibition of convergent nucleotide biosynthetic routes
and ATR in ALL. This combination is therapeutically exploitable
in vivo, resulting in long-term, disease-free survival in a systemic
p185BCR-ABLArf–/– pre-B-ALL mouse model representative of the
human disease31–33. Overall, our findings suggest that nucleotide
biosynthetic plasticity in lymphoblastic leukemia cells, and
potentially in other malignancies, is mediated by both ATR sig-
naling and nucleotide metabolic adaptive mechanisms which may
be targetable without overt toxicity to normal tissues, using
existing small molecule inhibitors.
Results
ATR and dCK Co-inhibition impairs G1/S transition. Human
T-ALL cells CCRF-CEM (CEM) express dCK and exhibit
constitutive phosphorylation of the ATR effector kinase CHEK1
on Serine 345 (pS345, Supplementary Fig. 1a), a marker of
replication stress34. CHEK1 pS345 levels are reduced following
exposure to VE-822, a specific ATR inhibitor35 (Supplementary
Fig. 1a). To investigate whether ATR inhibition increases the
dependence of T-ALL cells on dCK activity at the G1/S transition,
CEM cells were synchronized in G1 using Palbociclib, a CDK4/6
inhibitor36, 37, and then released into media containing VE-822
and/or DI-82, a high-affinity dCK inhibitor (dCKi) developed by
our group38. At various time points following G1 release, cells
were pulsed for 1 h with 5’-ethynyl-2’-deoxyuridine (EdU) to
analyze cell cycle kinetics by flow cytometry. Six hours after
release from G1, ~ 25% of cells in the untreated and single drug
treated groups advanced into early S-phase (designated as S1,
in blue, Fig. 1a). In contrast, only 16% of cells treated with both
VE-822 and dCKi entered S1. Twelve hours after release from
G1 arrest, 16% fewer VE-822-treated cells entered the later part of
S-phase (designated as S2, in red, Fig. 1b) compared to untreated
cells. While at this time point dCK inhibition alone did not affect
the number of cells that progressed beyond early S phase,
progression to late S-phase was significantly impeded (Supple-
mentary Fig. 1b). Co-inhibition of ATR and dCK decreased the
percentage of cells that reached S2 by fivefold relative to untreated
cells (Fig. 1b). The effects of ATR inhibition on cell cycle kine-
tics were partially rescued by nucleotide supplementation, in a
dCK-dependent manner (Supplementary Fig. 1c, d).
To further investigate the functions of dCK and ATR at the
G1/S transition in CEM cells, a non-targeted liquid chromato-
graphy mass spectrometry (LC-MS) assay was used to determine
the utilization of labeled [13C6]glucose and [13C9,15N3]deoxycy-
tidine, the main substrates for de novo and salvage nucleotide
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biosynthesis, respectively. Of the 166 metabolites identified in
CEM cells treated with VE-822 and/or dCKi, 105 metabolites
found in all four treatment groups contained glucose-derived 13C
atoms. While ATR inhibition did not decrease glucose uptake and
labeling of glycolytic intermediates (Supplementary Fig. 2), it
significantly decreased glucose utilization for 29 other metabolites
(Fig. 1c and Supplementary Data 1). These metabolites included
intermediates such as rUTP, rCTP and rCDP in the de novo
dCTP biosynthesis (Fig. 1d). These data indicate that ATR
inhibition impacts glucose utilization for de novo nucleotide
biosynthesis. However, several deoxyribonucleotides, including
dCTP, were below the limit of detection of the non-targeted
LC-MS approach, raising the concern that the sensitivity of this
assay is not sufficient to measure the contribution of the salvage
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Fig. 1 Effects of ATR and dCK inhibition on G1-S transition and substrate utilization for dCTP biosynthesis. a, b Flow cytometry analysis of EdU
incorporation in CEM T-ALL cells treated with VE-822 (1 µM) and/or dCKi (DI-82,1 µM) for 6 a and 12 h b following release from G1 arrest, respectively.
Bar graphs summarize the percentage of cell populations in S1 (early S-phase) and S2 (mid to late S-phase) at 6 and 12 h (mean± s.d., n= 2, one-way
ANOVA, Bonferroni corrected). Plots are representative of two independent experiments. c Comparison of metabolite labeling by [13C6]glucose in CEM T-
ALL cells treated with VE-822 and/or dCKi for 12 h following release from G1 arrest. Number of metabolites exhibiting alterations in [13C6]glucose labeling
greater than 15% with significance at a false discovery rate≤ 20% are indicated. d Percent glucose labeling of ribonucleotides intermediates in the de novo
dCTP biosynthesis (mean± s.d., n= 6, one-way ANOVA, Bonferroni corrected). e Workflow for targeted LC-MS/MS-MRM analysis of dCTP incorporated
into newly replicated DNA using a triple quadrupole mass spectrometer. See text for details and Supplementary Fig. 4 for the LC-MS/MS-MRM analysis of
dCTP pools. f, g Contributions of the de novo and salvage pathways to dCTP pools f and dCTP incorporated into newly synthesized DNA g in CEM cells
treated with VE-822 and/or dCKi after release from G1 arrest (mean± s.d., n= 3). Results are representative of two independent experiments. NT=Not
treated, V=VE-822, D= dCKi, V + D=VE-822 + dCKi. *P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001. ATR ataxia telangiectasia and Rad3-related
protein, EDU 5’-ethynyl-2’-deoxyuridine, FDR false discovery rate, RNR ribonucleotide reductase, CTPS1/2 CTP synthase 1/2, R5P ribose 5-phosphate,
OMP orotidine monophosphate, rCDP cytidine diphosphate, CTP cytidine triphosphate, UTP uridine triphosphate, dCTP deoxycytidine triphosphate,
LC-MS/MS-MRM liquid chromatography tandem mass spectrometry operating in multiple reaction monitoring
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pathway or the ratio of de novo and salvage biosynthesis to these
pools. To address this problem, a newly developed targeted MS
assay was developed (Fig. 1e and Supplementary Fig. 3). In this
assay, samples containing either extracted dNTPs or hydrolyzed
DNA from labeled cells are separated by LC for detection by a
triple quadrupole mass spectrometer using multiple reaction
monitoring (LC-MS/MS-MRM). The first (Q1) and third (Q3)
quadrupoles function as mass filters, while the second (Q2)
quadrupole serves as a collision chamber (Fig. 1e). For instance,
to profile the biosynthetic composition of deoxycytidine (dC)
derived from hydrolyzed DNA or dCTP, an intact, protonated dC
ion is selected in Q1, followed by fragmentation of the glycosidic
bond, which releases protonated cytosine in Q2, that is filtered in
Q3 and detected to generate an ion chromatogram. The peak
areas for the ion chromatograms of salvage [13C9,15N3]dC
(red trace), de novo [13C5]dC (black trace, from [13C6]glucose)
and unlabeled dC (gray trace) (Fig. 1e) are used to determine the
relative contributions of the de novo and salvage routes both to
dCTP pools and to DNA-incorporated dCTP.
Since dCK phosphorylates not only dC but also dA and dG5,
the targeted LC-MS/MS-MRM assay was used to determine
whether, in T-ALL cells, dCK mediates the salvage of multiple
deoxyribonucleosides (dNs). However, salvaging of purine
dNs via dCK occurred only if the catabolic enzymes which
degrade these dNs, adenosine deaminase (ADA) and purine
nucleoside phosphorylase (PNP), were inhibited pharmacologi-
cally (Supplementary Figs 4 and 5). Since inactivating mutations
in ADA and PNP have been associated with severe combined
immunodeficiency39, but not with cancer, we focused on
examining the metabolic fate of dC as the most relevant dCK
substrate in ATR-inhibited T-ALL cells for salvage biosynthesis.
CEM cells were collected at multiple points after release
from Palbociclib-induced G1 arrest into media containing
VE-822 and/or dCKi, as well as substrates for the de novo and
salvage pathways, [13C6]glucose and [13C9, 15N3]dC, respectively.
At each of the examined time points, free dCTP pools in
untreated cells were predominantly synthesized by the salvage
pathway from [13C9,15N3]dC via dCK, with only a small
contribution from [13C6]glucose via the de novo pathway (Fig. 1f).
While ATR inhibition alone did not alter free dCTP levels or
their biosynthetic origins (e.g., de novo vs. salvage), dCKi either
alone or in combination with VE-822, nearly eliminated the
contribution of the salvage pathway and reduced the amount of
free dCTP by ~ 50% at the 12 h time point.
In contrast to the free dCTP pool, which was predominantly
derived from the salvage pathway, dCTP incorporated into newly
replicated DNA of CEM cells was produced in equal proportions
by the de novo and salvage pathways (Fig. 1g and Table 1). This
observation is consistent with previous findings that de novo
synthesized dCTP is more readily incorporated in DNA than is
dCTP synthesized by the salvage pathway12. ATR inhibition
reduced the DNA incorporation of both de novo and salvage
produced dCTP, yielding a combined 30% reduction in overall
DNA labeling compared to untreated cells at the 12 h time point
(Fig. 1g and Table 1). This reduction is consistent with data in the
literature showing replication fork collapse and delays in
restarting DNA replication following ATR inhibition40–43. dCK
inhibition abolished the incorporation of salvage produced dCTP
into DNA and triggered a compensatory increase in the DNA
incorporation of de novo generated dCTP. This compensatory
response was suppressed in cells treated with both VE-822 and
dCKi (Fig. 1g and Table 1).
Effects of ATR inhibition on RRM2 and dCK. To investigate the
molecular mechanisms underlying the metabolic consequences of
ATR and dCK inhibition, global changes in protein expression
were assessed in CEM cells using quantitative nano-LC tandem
MS (nLC-MS/MS) (Fig. 2a). Chemical isotope coding following
reductive dimethylation of peptide N-termini and lysine primary
amines with differential stable isotopes (light:medium:heavy) was
used to compare expression of experimental (VE-822, dCKi and
VE-822 + dCKi) samples to controls (untreated, NT) by mixing
equal proportions for triplex nLC-MS/MS quantitative analyses.
The data set was filtered for proteins identified in all treatment
groups in three independent experiments with coefficients of
variation <20%. This yielded 1757 proteins with relative fold
changes in treated vs. untreated cells ranging from 0.45 to 1.83.
Of these, ~3% (46 proteins) displayed statistically significant
(as determined by one-way ANOVA and false discovery
rate cutoffs) fold changes in expression (>20%) in at least one
treatment group (Fig. 2b and Supplementary Data 2). Protein
levels of both RNR subunits, RRM1 and RRM2, as well as
thymidylate synthase decreased by more than 20% following ATR
inhibition (Fig. 2c). Changes in the expression of de novo
enzymes observed in synchronous cells also occurred with
ATR inhibition in asynchronous CEM cells (Fig. 2d and
Supplementary Data 3), thereby arguing against the possibility of
experimental artifacts introduced by Palbociclib-mediated cell
cycle synchronization. The reduction in RRM2 levels induced by
ATR inhibition was accompanied by an ~ 50% decrease in the
phosphorylation of RRM2 on threonine 33 (pT33) (Fig. 2e), a
phosphosite previously linked to the RRM2 stability44.
ATR inhibition decreased dNTP levels in several solid tumor-
derived cell lines and has been linked to reduced RRM2 levels26,
45. However, it remains unclear to what degree RRM2 protein
levels are rate-limiting for de novo dCTP biosynthesis. To further
investigate the relationship between RRM2 protein levels and
dCTP biosynthesis, we knocked down RRM2 in CEM cells using
shRNA (Supplementary Fig. 6a). RRM2 levels in the CEM
shRNARRM2 cells were reduced by 35–50%, as determined by
quantitative nLC-MS/MS and intracellular flow cytometry
analyses (Supplementary Fig. 6a, b). CEM shRNARRM2 cells
exhibited ~30% lower incorporation of de novo synthesized dCTP
into newly replicated DNA compared to control cells (Supple-
mentary Fig. 6c); a response comparable with the effects of
pharmacological ATR inhibition (Fig. 1g). These findings suggest
that the RRM2 regulation by ATR is an important determinant of
de novo dCTP biosynthesis in T-ALL cells. Since ATR inhibition
reduced RRM2 levels by only 20%, it is likely that there are
Table 1 Rates of de novo and salvage produced dCTP incorporation into newly replicated DNA
Treatment De novoa Salvagea Ratio (salvage/de novo)
Not treated 0.20± 0.01 0.17± 0.01 0.83
VE-822 0.17± 0.01 0.14± 0.01 0.85
dCKi 0.23± 0.01 0.019± 0.004 0.082
VE-822 + dCKi 0.19± 0.01 0.022± 0.002 0.12
aSlope± standard error of regression line in arbitrary unit
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other mechanisms by which ATR regulates de novo dCTP
biosynthesis. These additional mechanisms could include reduced
levels of the large RNR subunit, RRM1 (Figs. 2c, d),
and/or changes in yet to be identified regulatory PTMs in
RRM1 and RRM2 that are modulated directly or indirectly by
ATR signaling.
In contrast to the reduced RRM1 and RRM2 levels in
response to ATR inhibition, dCK protein levels were not affected
(Fig. 2c, d). ATR was shown to directly phosphorylate dCK on
serine 74 (dCK pS74) to control its activity under replication
stress28. We therefore quantified the effects of ATR inhibition on
the biosynthetic output and phosphorylation status of dCK. Used
as a positive control, the dCKi reduced dCK activity, as defined by
contribution of labeled [13C9,15N3]dC to intracellular dCMP, by
~ 90% (Fig. 2f, left panel). ATR inhibition in CEM cells reduced
the dCK-labeled [13C9,15N3]dCMP pool by ~ 33% compared to
untreated cells (Fig. 2f, left panel). The reduction in dCMP
biosynthesis following ATR inhibition correlated with a ~ 36%
decrease in dCK pS74 levels (Fig. 2f, right panel). Collectively,
these data (summarized in Fig. 2g) show that, in T-ALL cells,
ATR regulates de novo and salvage pathways by diverse
mechanisms involving alterations in total protein (ATR) and
protein phosphorylation (dCK) levels. Nonetheless, both de novo
and salvage pathways retain significant activity in ATR inhibited
CEM cells.
Increased salvage dCTP biosynthesis by RNR inhibition. To
identify the most potent clinically relevant RNR inhibitors that
could be used to target the remaining de novo nucleotide
biosynthetic activity in ATR inhibited CEM cells we evaluated
four compounds, each with a distinct mechanism of action:
(3-AP)46, 47, hydroxyurea (HU)48, gallium maltolate (GaM)49 and
thymidine (dT)50 (Fig. 3a). Amongst these, 3-AP was the most
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of the observed effects of ATR and dCK inhibition in CEM cells. ↓ partial decrease/inhibition, ↓↓↓ nearly complete inhibition, ↑ increase,⟷ no change,
nd not determined. NT=Not treated, V=VE-822, D= dCKi, V + D=VE-822 + dCKi. *P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001. nLC-MS/MS
nano liquid chromatography tandem mass spectrometry, RRM1 ribonucleotide reductase subunit 1, RRM2 ribonucleotide reductase subunit 2,
TYMS thymidylate synthase, dCK deoxycytidine kinase, dCMP deoxycytidine monophosphate
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potent, as indicated by induction of S-phase arrest at
concentrations as low as 0.5 µM (Fig. 3b and Supplementary
Fig. 7). In contrast, 60–100-fold higher concentrations of HU,
GaM and dT were required to induce S-phase arrest. The effects
of 3-AP on the utilization of [13C6]glucose and [13C5, 15N3]dC for
nucleotide biosynthesis in CEM cells were investigated (Fig. 3c),
using the targeted LC-MS/MS-MRM assay. 3-AP doubled the
rCTP and rCDP pools, likely reflecting an inefficient conversion
of these pools to dCDP via RNR. However, the most significant
change in 3-AP treated cells was a ~ 19-fold reduction in the
incorporation of de novo produced dCTP into DNA. Along with
its effects on de novo biosynthesis, 3-AP triggered a compensa-
tory upregulation of the salvage pathway. Salvage dC nucleotide
pools doubled in size following 3-AP treatment, and the
incorporation of salvage-produced dCTP into DNA increased by
>1.5-fold, thereby providing a potential mechanism of resistance
to RNR inhibition by 3-AP (Fig. 3c).
Triple combination induces lethal replication stress in vitro.
We next quantified the impact of combined ATR, dCK and RNR
inhibition on the de novo and salvage dCTP biosynthesis in
asynchronous CEM cells (Fig. 4a and Supplementary Data 4).
ATR inhibition decreased the [13C6]glucose labeling of the rCDP
pool by 40% (Fig. 4a, rCDP panel), an effect similar to that
observed in the synchronous model (Fig. 1d). In contrast, RNR
inhibition increased the size of the rCDP pool (Fig. 4a, rCDP
panel, 3-AP). While neither ATR nor RNR inhibition alone had a
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statistically significant impact on the de novo contributions to the
dCDP, dCMP and dCTP pools, these pools were nearly abolished
when both ATR and RNR were inhibited simultaneously.
However, the salvage biosynthetic contributions to the dCMP,
dCDP and dCTP pools remained substantial in the absence of the
dCKi. In fact, RNR inhibition, alone or combined with ATR
inhibition, increased the salvage contributions to the dCMP,
dCDP and dCTP pools by approximately twofold, indicative of a
compensatory mechanism. dCK inhibition abolished this
adaptive mechanism to augment these deoxyribonucleotide pools.
Consequently, the rate of dCTP incorporation into DNA was
lowest when all three enzymes were inhibited (Fig. 4a, DNA
panel).
Persistent nucleotide insufficiency triggers replication
stress characterized by the accumulation of single-stranded
DNA (ssDNA) at stalled replication forks, followed by DNA
double-stranded breaks51. To investigate these events we used
flow cytometry and antibodies against ssDNA52 as an indicator of
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replication stress, and phosphorylated histone H2A.X on serine
139 (pH2A.X) as an indicator of DNA damage (Fig. 4b). RNR
inhibition by 3-AP increased the percentage of ssDNA+ cells by
more than two-fold as early as 0.5 h after treatment, and by
greater than three-fold at the 4 h time point. Combined inhibition
of ATR and dCK also increased the ssDNA+ and ssDNA+;pH2A.
X+ cell populations at the 0.5 and 4 h time points. Addition of an
RNR inhibitor resulted in a rapid and massive expansion of
ssDNA+ population at the 0.5 h time point compared to
untreated cells, an effect which was further amplified at the later
time point (Fig. 4b). Along with these changes, RNR inhibition
triggered rapid induction of CHEK1 pS345, a direct downstream
target of ATR (Fig. 4c). This PTM was abrogated by VE-822
treatment at the 0.5 h time point and partially inhibited at the 4 h
time point. The rebound in CHEK1 pS345 expression at the 4 h
time point was likely mediated by the ATR related kinase, ataxia
telangiectasia mutated (ATM), which also phosphorylates
CHEK1 on serine 34553. ATM was activated in cells treated with
the triple combination therapy, as indicated by an increase in
phosphorylation of CHEK2 on threonine 68 (pT68, Fig. 4c); a
direct target of activated ATM. The induction of CHEK2 pT68 in
cells treated with the triple combination therapy coincided with
an increase in the pH2A.X+ population (Fig. 4b) and with
cleavage of the apoptotic markers caspase 8 (but not caspase 9),
caspase 3, and Poly (ADP-ribose) polymerase (PARP) (Fig. 4c).
Consistent with these observations, co-targeting ATR, dCK, and
RNR resulted in the highest percentage of apoptotic cells, as
measured by Annexin V staining (Supplementary Fig. 8a). The
cytotoxic effect of ATR inhibitors has been attributed to the
induction of premature mitotic entry of cells undergoing DNA
replication, an event that exacerbates the level of replication stress
and DNA damage54, 55. Consistent with this model, ATR
inhibition increased the percentage of S-phase CEM cells with
phosphorylation of histone 3 on serine 10 (H3 pS10), a marker
for mitotic kinase activation. This effect was significantly
amplified in the triple combination therapy (Supplementary
Fig. 8b).
ATR inhibition alone is marginally effective in vivo. To
investigate the in vivo efficacy and tolerability of co-targeting
alternative nucleotide biosynthetic pathways and ATR, we used a
previously described primary BCR-ABL-expressing Arf-null pre-B
(p185BCR-ABLArf–/–) model which is difficult-to-treat and thought
to be representative of the human disease31, 33. When compared
with 31 cancer cell lines of different origins, p185BCR-ABLArf–/–
cells were amongst the most sensitive to ATR inhibition by
VE-822, with an IC50 value of ~ 300 nM (Fig. 5a). However,
despite its high potency in culture against pre-B-ALL cells,
VE-822 alone was only marginally efficacious in vivo. C57BL/6
mice inoculated with luciferase expressing p185BCR-ABLArf–/–
cells succumbed to disease within 17 days; all VE-822 treated
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mice died of leukemia within 38 days after inoculation
(Fig. 5b–d). We then investigated whether targeting the activities
of de novo and salvage pathways can improve the efficacy of ATR
inhibition in p185BCR-ABLArf–/– cells. Similar to the findings in
the human T-ALL cells, targeting these biosynthetic pathways
along with ATR was necessary to achieve maximal induction
of cell death (Fig. 5e) and complete inhibition of cell growth
(Supplementary Fig. 9a, b).
Triple combination eradicates B-ALL in vivo. To translate the
above cell culture findings into an in vivo setting, we developed a
new drug formulation consisting of PEG-200, Transcutol,
Labrasol and Tween-80 blended in a ratio of 5:3:1:1 to solubilize
three different drugs (3-AP, VE-822 and dCKi) and achieve
therapeutically relevant plasma concentrations via oral delivery
(Fig. 6a). Based on plasma pharmacokinetic parameters, 3-AP
and dCKi were administered twice/day while VE-822 was
administered once/day (Fig. 6b). Treatment was initiated on day 7
post inoculation of pre-B-ALL when all mice showed evidence of
systemic disease, as indicated by whole body bioluminescence
imaging (BLI, Fig. 6c, top row, right panel). While mice in the
control group succumbed to disease within 17 days, mice in the
combination treatment group had significantly lower disease
burden on day 17 (Fig. 6c, d). All treated mice remained disease-
free for 442 days after treatment withdrawal on day 42 (Fig. 6e).
The combination therapy was well-tolerated, as indicated by
maintenance of body weight during treatment (Fig. 6f) and long
term survival (over 1 year and currently ongoing) without any
detectable pathology. We also assessed the efficacy of the
combination therapy when all three components were
administered once daily. Although this therapeutic scheme
appeared to be slightly less efficacious than the twice/day schedule
for 3-AP and dCKi, it was well tolerated and four out of five mice
had no detectable disease 313 days after treatment withdrawal
(Supplementary Fig. 10). Importantly, removing the dCKi from
the combination therapy significantly reduced the therapeutic
efficacy in vivo (Supplementary Fig. 11), a result consistent with
cell culture findings (Figs 4 and 5e, Supplementary Figs 8 and 9).
While BCR-ABL tyrosine kinase inhibitors are becoming
standard care for patients with Philadelphia chromosome positive
ALL56, therapeutic resistance in pre-B-ALL is common and is
caused by the rapid emergence of the T315I BCR-ABL kinase
domain (gatekeeper) mutation32, 56. To test the combination of
VE-822, dCKi and 3-AP against kinase inhibitor resistant ALL we
generated p185BCR-ABLArf–/– T315I mutant cells by exposing
leukemia bearing mice to dasatinib and harvesting drug-resistant
cells from bone marrow (Supplementary Fig. 12a–c). Mice were
inoculated with the T315I-positive cells and treated with the
combination therapy (Supplementary Fig. 12d–g). The combina-
tion therapy was effective against the highly aggressive dasatinib
resistant in vivo pre-B-ALL model with 13 out of 20 mice being
disease-free over 365 days post inoculation of leukemia cells
(Supplementary Fig. 12). To determine whether mice that did not
achieve complete remissions harbor ALL cells that have acquired
resistance to the triple combination, we harvested leukemia cells
from the bone marrow of the moribund mice. These cells were
then used to test the efficacy of the combination treatment in cell
culture, and compare it with the original dasatinib-resistant
p185BCR-ABLArf–/– pre-B-ALL cells. The harvested leukemia cells
responded to the combination treatment as well as did the
parental cells (Supplementary Fig. 13). One potential reason for
the incomplete response in some of the treated mice is the rapid
engraftment of p185BCR-ABLArf–/– T315I + pre-B-ALL cells in the
brain coupled with the suboptimal penetrability of 3-AP and
potentially, dCKi across the blood–brain-barrier.
Discussion
Here we show that ATR inhibition in leukemia cells reduces the
output of both de novo and salvage pathways. However,
significant remaining activities of both pathways were sufficient
to prevent ATR inhibition-induced DNA replication shutdown in
cell culture, and permit disease-induced lethality in a systemic
mouse model of pre-B-ALL. Combining ATR inhibition with
inhibitors of de novo (RNR) and salvage (dCK) rate-limiting
enzymes led to rapid accumulation of ssDNA, a hallmark
of replication stress22, followed by extensive DNA damage,
caspase-8 and PARP cleavage, and apoptosis. This synthetically
lethal combination therapy was well-tolerated in vivo and
promoted long-term disease-free survival in mice with systemic
p185BCR-ABLArf–/– pre-B-ALL, as well as in a mouse model of
targeted-therapy (dasatinib) pre-B-ALL resistance. Collectively
our results quantify the control exerted by ATR on convergent
nucleotide biosynthetic routes, and provide the rationale to
co-target both signaling (ATR) and metabolic (RNR and dCK)
mechanisms in acute leukemia for optimal therapeutic efficacy.
In mammalian cells dCTP and other dNTPs are present in low
concentrations (1–50 pmol of dCTP/106 cells); amounts
far below those required to complete one round of genome
duplication (~ 1089 pmol of dCTP/106 cells)14, 57. This apparent
discrepancy between dNTP supply and demand can be explained
by a model in which dNTP production is tightly coupled
with utilization for DNA synthesis—an ‘on demand’ model.
According to this model, even small disruptions of dNTP
production could significantly impact DNA integrity, unless
the demand for dNTPs is reduced by preventing new origin
firing, a process regulated by ATR and its effector kinases43.
This prediction is supported by the synthetic lethality observed
with ATR inhibition and pharmacological targeting of the
de novo and salvage pathways observed in cell culture (Fig. 5e and
Supplementary Figs 8, 9 and 13) and in vivo (Fig. 6c–f, Supple-
mentary Figs 10–12).
To what extent are our findings of differential utilization of de
novo and salvage pathways in leukemia applicable to solid
tumors? An examination of three patient-derived primary cells
point to significant nucleotide biosynthetic diversity in solid
tumors (Supplementary Fig. 14a). HK-374 glioblastoma multi-
forme cells58 preferentially use the de novo pathways to generate
most of their dATP, dGTP and dCTP pools, with only the dTTP
pool displaying a significant salvage component. A distinct
nucleotide biosynthetic profile is present in two melanoma
patient-derived primary cells, M299 and M417 (Supplementary
Fig. 14a). In M299 cells, the salvage contribution to all four
dNTPs exceeds 50%. Except for dATP, a similarly increased
reliance on salvage biosynthesis was evident in M417 cells
(Supplementary Fig. 14a). In contrast, de novo pyrimidine bio-
synthesis is almost completely absent in M417 cells, with greater
than 98% of the dTTP and dCTP pools originating from salvage
pathways. Stable isotope labeling studies using [15N2]orotate
show that both M417 and M229 patient-derived primary cells
efficiently used this substrate to produce dCTP, thereby
suggesting a block in de novo pyrimidine biosynthesis in M417
cells either at the level of carbamoylphosphate synthetase II
(CAD) or at the level of dihydroorotate dehydrogenase (Supple-
mentary Fig. 14b, c). Indeed, M417 cells were subsequently found
to harbor a homozygous nonsense mutation (Q140*) in CAD
(Supplementary Fig. 14d). Predictably, the defect in de novo
pyrimidine biosynthesis rendered M417 cells hypersensitive to
dCK inhibition (Supplementary Fig. 14e). Confirmation of these
findings in larger panels of cell lines and patient-derived primary
samples would provide the rationale for developing new
metabolically targeted therapies and clinically applicable
biomarkers to define specific nucleotide biosynthetic subtypes
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(e.g. predominant de novo, predominant salvage, and both de
novo and salvage) in solid tumors. Such biomarkers could be
provided by positron emission tomography imaging using new
probes for nucleotide metabolism developed by us59, 60 as well as
by others61.
PTMs can have profound and dynamic effects on the activity of
metabolic networks62. Both dCK30 and RRM244, 63 contain
multiple PTMs. Among the four phosphorylation sites reported
for dCK30, phosphorylation on serine 74 (pS74) is an important
determinant of dCK substrate specificity and catalytic activity29.
Both ATR and ATM have been reported to phosphorylate dCK
on S74 in response to replication stress and DNA damage
respectively28, 64. Our data show that the ATR inhibitor VE-822
reduces dCK activity by ~ 33%, an effect likely attributed to a
two-fold decrease in dCK pS74 (Fig. 2f). However, it remains
unknown what kinases are responsible for the remaining dCK
pS74 present in VE-822-treated leukemia cells. ATM is a
potential candidate, given that phosphorylation of CHEK2 on
T68 is detected in ATR inhibited cells (Fig. 4c). Further studies
are needed to confirm this hypothesis. In this context, it may
also be informative to analyze the activity of dCK following
ATR inhibition in tumors harboring inactivating mutations in
ATM65–67. Concerning RNR regulation, the observed
consequences of ATR inhibition in T-ALL cells include the fol-
lowing: a decrease in RRM2 protein levels (Fig. 2c, d), reduced
RRM1 protein levels (Fig. 2c, d), and a significant reduction in
RRM2 pT33 (Fig. 2e), a CDK-mediated phosphorylation event
which promotes RRM2 proteasomal degradation via interactions
with the SCFCyclin F ubiquitin ligase complex44. It is currently
unknown whether the reduction in RRM2 levels by ATR inhi-
bition in leukemia cells occurs via a post-translational mechanism
concerning protein stability and/or by a transcriptional
mechanism downstream of E2F family members68, 69. Moreover,
further studies are needed to determine the significance of the
observed reductions in RRM1 protein levels following ATR
inhibition (Fig. 2c, d) and to identify the mechanism(s) respon-
sible for this effect.
Our results provide quantitative insights into alterations of
nucleotide biosynthetic pathways induced in leukemia cells by
inhibiting ATR and rate-limiting de novo (RNR) and salvage
(dCK) enzymes. These findings support a new therapeutic
strategy that uses existing inhibitors to exploit the dependency of
leukemia cells on intact de novo and salvage biosynthetic
pathways and replication stress response mechanisms. Further
refinements in this strategy and expanding its applicability
beyond leukemia may come from follow-up studies to define
clinically applicable companion biomarkers capable of delineating
nucleotide biosynthetic and replication stress subtypes that are
predictive of responses in human tumors.
Methods
Cell culture and culture conditions. Leukemia cell lines: CCRF-CEM, EL4, Jurkat,
Molt-4, CEM-R, THP-1, HL-60, TF-1, MV-4-11, HH, HuT 78, K-562; ovarian
cancer cell lines: Hey-T30, PA-1, Caov-3, OVCAR-5, IGROV-1, A2780; and
pancreatic adenocarcinoma cell lines: BxPC-3, MIA PaCa-2, Hs 766 T, AsPC-1 and
PANC-1 were obtained from American Type Culture Collection (ATCC). Various
cell lines were kind gifts: Nalm-6 (Michael Teitell, UCLA), p185BCR-ABLArf−/− pre-
B cells (N. Boulos, CERN Foundation), L3.6pl (David Dawson, UCLA), KPC
(Guido Eibl, UCLA), and patient-derived primary cells of leukemia COG332
(Yong-Mi Kim, USC). All hepatocellular carcinoma cell lines were gifts from Ali
Zarrinpar (Univ. of Florida): SNU-475, PRC/PRF/5, SNU-449, Hep 3B, Hep G2,
and SK-HEP-1. Patient-derived primary cells of glioblastoma (HK-374) and mel-
anoma (M299 and M417) were derived in the labs of Drs. Kornblum (UCLA) and
Ribas, respectively. With a few exceptions, cell lines were cultured in RPMI-1640
(Corning) containing 10% fetal bovine serum (FBS, Omega Scientific) and were
grown at 37 °C, 20% O2 and 5% CO2. p185BCR-ABLArf−/− pre-B cells were cultured
in RPMI-1640 containing 10% FBS and 0.1% β-mercaptoethanol. HK374
was cultured in DMEM-F12 (Invitrogen) containing B27 supplement
(Life Technologies), 20 ng ml−1 basic fibroblast growth factor (bFGF; Peprotech),
50 ng ml−1 epidermal growth factor (EGF; Life Technologies), penicillin/strepto-
mycin (Invitrogen), Glutamax (Invitrogen) and 5 µg ml−1 heparin
(Sigma-Aldrich). All cultured cells, except HK374, were incubated in antibiotic
free media and were regularly tested for mycoplasma contamination using
MycoAlert kit (Lonza) following the manufacturer’s instructions, except that
the reagents were diluted 1:4 from their recommended amount.
Proliferation assays. Cells were plated in 384-well plates (1000 cells/well for
suspension cell lines and 500 cells/well for adherent cell lines in 30 µl volume).
Drugs were serially diluted to the desired concentrations and an equivalent volume
of DMSO was added to vehicle control. Ten microliter of the 4× diluted drugs were
added to each well. Following 72 h incubation, ATP content was measured using
CellTiter-Glo reagent according to manufacturer’s instructions (Promega,
CellTiter-Glo Luminescent Cell Viability Assay), and analyzed by SpectraMax
luminometer (Molecular Devices). IC50 values, concentrations required to inhibit
proliferation by 50% compared to DMSO treated cells, were calculated using Prism
6.0 h (Graphpad Software).
Isotopic labeling in cell culture. Cells were transferred into RPMI-1640 without
glucose and supplemented with 10% dialyzed FBS (Gibco) containing the following
labeled substrates: precursors for de novo [U-13C6]glucose (Sigma-Aldrich,
389374) at 11 mM; precursors for purine salvage [U-13C10,15N5]dA (Cambridge
Isotopes, CIL 3896), [15N5]dA (Cambridge Isotopes, NLM-3895) and [15N5]dG
(Cambridge Isotopes, NLM-3899) at 5 µM or as indicated; and precursors for
pyrimidine salvage: [U-13C9,15N3]dC (Silantes, 124603602) and [U-13C10,15N2]dT
(Cambridge Isotopes, CNLM-3902) at 5 µM and [15N2]orotate (Cambridge
Isotopes, NLM-1048) at indicated concentrations. The cells were incubated for 12 h
or as indicated before sample collection and processing.
Western blot. Cells were lysed using RIPA buffer supplemented with protease
(ThermoFisher, 78,430) and phosphatase (ThermoFisher, 78,420) inhibitors,
scraped, sonicated, and centrifuged (20,000 × g at 4 °C). Protein concentrations in
the supernatant were determined using the Micro BCA Protein Assay kit
(Thermo), and equal amounts of protein were resolved on pre-made Bis-Tris
polyacrylamide gels (Life Technologies). Primary antibodies: pS345 CHEK1 (Cell
signaling, #2348 L, 1:1000), pT68 CHEK2 (Cell signaling, #2197 S, 1:1000), pS139
H2A.X (Millipore, 05-636, 1:1000), clvd. Casp8 (Cell signaling, #8592, 1:1000),
clvd. Casp9 (Cell signaling, #9502, 1:1000), clvd. Casp3 (Cell signaling, #9662,
1:1000), clvd. PARP (Cell signaling, #5625 P, 1:1000), and anti-actin (Cell Signaling
Technology, 9470, 1:10,000). Primary antibodies were stored in 5% BSA
(Sigma-Aldrich) and 0.1% NaN3 in TBST solution. Anti-rabbit IgG HRP-linked
(Cell Signaling Technology, 7074, 1:2500) and anti-mouse IgG HRP-linked
(Cell Signaling Technology, 7076, 1:2500) were used as secondary antibodies.
Chemiluminescent substrates (ThermoFisher Scientific, 34,077 and 34,095)
and autoradiography film (Denville) were used for detection.
Drugs. The following drugs were used: Pablociclib (Selleckchem, S1116, 1 µM),
VE-822 (ApeXBio, B1381, 1 µM or as indicated), DI-82 (dCKi2, 1 µM), thymidine
(Sigma-Aldrich, T1895, as indicated), hydroxyurea (Sigma-Aldrich, H8627, as
indicated), gallium maltolate (Nanoman Industries, CN-GAM-02-1G00-A00, as
indicated), 3-AP (ApeXBio, custom, 500 nM or as indicated), Pentostatin
(Santa Cruz Biotechnology, sc-204177, 10 µM), forodesine or BCX-1777
(Chemscene, CS-3781, 100 nM), and dasatinib (LC Laboratories, D-3307, 1 nM).
Cell cycle kinetics. CEM T-ALL cells were synchronized in G1 phase, and then
treated as indicated. Cells were pulsed with EdU 1 h before collection at different
time points. Cells were fixed 4% paraformaldehyde, permeabilized with perm/wash
reagent (Invitrogen), stained with Azide-AF647 (using click-chemistry, Invitrogen;
Click-iT EdU Flow cytometry kit, #C10634) and FxCycle-Violet (Invitrogen),
and then analyzed flow cytometry (a detailed description is available in the
Supplementary Information).
Metabolite profiling. See Supplementary Information for details on sample
preparation, data collection and analysis.
Global proteomic and phosphoproteomic analyses. See Supplementary
Information for details on sample preparation, data collection and analysis.
ssDNA and pH2A.X Measurements. Treated CEM T-ALL cells were fixed with
ice-cold methanol:PBS (6:1 v/v). Staining with F7-26 ssDNA monoclonal antibody
(mouse) was performed according to manufacturer’s instructions (EMD Millipore,
#MAB3299) followed by secondary antibody IgM-PE. Subsequently, cells were
stained with the phospho-Histone H2A.X (pS139 H2A.X) specific antibody
conjugated to FITC (EMD Millipore, #05-636) and DAPI, and then analyzed
by flow cytometry (a detailed description is available in the Supplementary
Information).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00221-3 ARTICLE
NATURE COMMUNICATIONS |8:  241 |DOI: 10.1038/s41467-017-00221-3 |www.nature.com/naturecommunications 11
Western blots. See Supplementary Information for details on sample preparation
and antibody information. Images have been cropped for presentation. Full-size
images are presented in Supplementary Fig. 15.
Apoptosis assay. Apoptosis and cell death were assayed using Annexin V-FITC
and PI according to manufacturer’s instructions (FITC Annexin V Apoptosis
Detection Kit, BD Sciences, #556570).
In vivo leukemia models and treatment regimes. All animal studies were
approved by the UCLA Animal research committee (ARC). For development of
systemic leukemia model, C57Bl/6 female mice were injected intravenously with
50,000 firefly luciferase expressing p185BCR-ABLArf−/− pre-B-ALL cells12, 31. The
leukemic burden was monitored using bioluminescence imaging. All drug
treatments were performed in an oral formulation consisting of PEG-200,
Transcutol, Labrasol and Tween-80 blended in a ratio of 5:3:1:1. The oral
gavage volume was 50 µl per dose (a detailed description is available in the
Supplementary Information).
Pharmacokinetic measurements. 3-AP, dCKi, VE-822 plasma concentrations
were assessed at 0.5, 1, 2, 4, 6, 12 and 24 h following oral administration. Blood
samples were collected in heparin-EDTA tubes by the retro-orbital technique and
spun down to collect the supernatants. Four parts of methanol were added to
plasma samples to precipitate proteins, and the supernatant was collected. Twenty
microliter samples were injected onto a reverse phase column equilibrated in water
0.1% formic acid for LC-MS/MS-MRM analysis in positive ion mode. Plasma
concentrations were determined by comparison to previously generated standard
curves. A population pharmacokinetic modeling (NONMEM v. 7.2) with first-
order conditional estimation (FOCE) was used to characterize the Cmax, half-life,
and area under the curve (AUC) for 3-AP, dCKi, and VE-822. 3-AP and VE-822
were best described with a one compartment model while dCKi was best described
by a two-compartment model. All three drugs were well described with first
order absorption and a proportional error model. Clearance and volume were
scaled by weight.
FACS analyses. All flow cytometry data were acquired on a five-laser LSRII
cytometer (BD), and analyzed using the FlowJo software (Tree Star). See
Supplementary Information for details on propidium iodide, cell cycle by EdU,
pH2A.X, ssDNA, phospho-histone 3 and Annexin V staining.
Animal studies. Mice were housed under specific pathogen-free conditions and
were treated in accordance with UCLA Animal Research Committee protocol
guidelines. All C57BL/6 female mice were purchased from the UCLA Radiation
Oncology breeding colony. VE-822 (ApeXBio, 40 mg kg–1), 3-AP (ApeXBio,
dosage as indicated) and DI-82 (dCKi, Sundia Pharmaceuticals, 50 mg kg–1)
were administered by intraperitoneal (i.p.) injections or oral gavage to recipient
animals. For oral administration, single agent or combination of drugs were
solubilized in a formulation consisting of the following: PEG-200: Transcutol:
Labrasol: Tween-80 mixed in 5:3:1:1 ratio. For i.p. administration, the drugs
were solubilized in PEG-400 and 1 mM Tris-HCl in a 1:1 (v:v) ratio. Dasatinib
(LC Laboratories) was solubilized in 80 mM citric acid (pH 3.1) and was
administered at a dose of 10 mg kg–1 by oral gavage. 2 × 105 luciferase expressing
p185BCR-ABLArf−/− pre-B-ALL cells were injected intravenously into C57BL/6
female mice for leukemia induction. The treatment was started 6 or 7 days after the
intravenous inoculation of leukemia initiating cells, when animals had developed a
significant leukemic burden as monitored by bioluminescence imaging (IVIS
Bioluminescence Imaging scanner). The dosing schedules are indicated in the text
and figure legends. The mice were observed daily and those that became moribund
during the trials, (paralysis of hind limbs, significant body weight loss) were
sacrificed immediately. Kaplan–Meier curves and bioluminescence quantifications
were generated using Prism 6.0 h (Graphpad Software).
Bioluminescence imaging (BLI). Mice were anesthetized with 2% isoflurane
followed by intraperitoneal injection of 50 μl (50 mgml−1) substrate D-luciferin
(Sigma, #L9504). The mice were imaged with the IVIS 100 Bioluminescence
Imaging scanner 10 min after luciferin administration. All mice were imaged in
groups of five with 1-minute exposure time, and the images were acquired at low
binning.
Statistical analyses. Data are presented as means ± s.d. with indicated biological
replicates. Comparisons of two groups were calculated using indicated unpaired or
paired two-tailed Student’s t-test and P values less than 0.05 were considered
significant. For some experiments, generated mean normalized values (ratios from
two groups, treated to untreated) were compared to the hypothetical value 1
(indicating equal values between treated and untreated), calculated using
one-sample t-test, and P values less than 0.05 were considered significant.
Comparisons of more than two groups were calculated using one-way ANOVA
followed by Bonferroni’s multiple comparison tests, and P values less than 0.05 /m,
where m is the total number of possible comparisons, were considered significant.
All statistical analysis and generated graphs were performed either in R or
Graphpad Prism 6.0 h.
The rates of dCTP incorporation into the DNA were determined using linear
regression with procedure GLM in SAS (v. 9.4). DNA % label was transformed
using a shifted log addition of 1 due to the presence of zeros in the data set. Rates
were calculated using the slope of the regression line for the log transformed data
and are presented in the table with the associated standard errors, along with the
ratio between the rate of incorporation into DNA by the de novo and salvage
pathways (Table 1).
Data availability. The proteomic and phosphoproteomic data have been deposited
in the Proteome Xchange database under accession code PXD006702. The authors
declare that all other data supporting the findings of this study are available within
the article and its Supplementary Information Files or from the corresponding
author upon request.
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